ATE286885T1 - Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten - Google Patents

Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten

Info

Publication number
ATE286885T1
ATE286885T1 AT97948290T AT97948290T ATE286885T1 AT E286885 T1 ATE286885 T1 AT E286885T1 AT 97948290 T AT97948290 T AT 97948290T AT 97948290 T AT97948290 T AT 97948290T AT E286885 T1 ATE286885 T1 AT E286885T1
Authority
AT
Austria
Prior art keywords
guanidyl
alpha
heterocyclic compounds
adrenoceptor agonists
adrenoceptor
Prior art date
Application number
AT97948290T
Other languages
English (en)
Inventor
Thomas Lee Cupps
Sophie Eva Bogdan
Raymond Todd Henry
Russell James Sheldon
William Lee Seibel
Jeffrey Joseph Ares
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE286885T1 publication Critical patent/ATE286885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT97948290T 1996-11-25 1997-11-21 Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten ATE286885T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3202396P 1996-11-25 1996-11-25
PCT/US1997/020802 WO1998023596A1 (en) 1996-11-25 1997-11-21 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
ATE286885T1 true ATE286885T1 (de) 2005-01-15

Family

ID=21862692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948290T ATE286885T1 (de) 1996-11-25 1997-11-21 Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten

Country Status (25)

Country Link
US (3) US6225331B1 (de)
EP (1) EP0944604B1 (de)
JP (1) JP2001506600A (de)
KR (1) KR20000069131A (de)
CN (1) CN1104422C (de)
AR (1) AR009145A1 (de)
AT (1) ATE286885T1 (de)
AU (1) AU730369B2 (de)
BR (1) BR9713536A (de)
CA (1) CA2272640C (de)
CO (1) CO4910148A1 (de)
CZ (1) CZ184099A3 (de)
DE (1) DE69732244T2 (de)
ES (1) ES2236833T3 (de)
HU (1) HUP0000312A3 (de)
ID (1) ID23857A (de)
IL (1) IL130077A0 (de)
NO (1) NO313912B1 (de)
NZ (1) NZ336010A (de)
PE (1) PE16399A1 (de)
RU (1) RU2194700C2 (de)
SK (1) SK69799A3 (de)
TR (1) TR199901468T2 (de)
WO (1) WO1998023596A1 (de)
ZA (1) ZA9710578B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901468T2 (xx) 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� guanidinil heterosikl bile�ikleri.
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
MXPA03001437A (es) * 2000-09-08 2005-06-03 Warner Lambert Co Prevencion de sinusitis aguda y crisis sinusal.
ES2278016T3 (es) * 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
PT1551834E (pt) * 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
CA2523015A1 (en) * 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
RU2254855C2 (ru) * 2003-09-10 2005-06-27 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Противовирусное средство и способ его получения
MXPA06005736A (es) * 2003-11-19 2006-12-14 Chiron Corp Compuestos de quinazolinona con bioacumulacion reducida.
ZA200709038B (en) * 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
TWI417099B (zh) * 2007-03-23 2013-12-01 Neuraxon Inc 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
WO2009062318A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
GB0919889D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CN112047947A (zh) * 2020-10-13 2020-12-08 石药集团新诺威制药股份有限公司 一种茶碱的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU148414A1 (ru) * 1961-07-03 1961-11-30 Е.Н. Зильберман Способ получени имидазолов и оксазолов
US3908013A (en) 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3947455A (en) 1974-04-15 1976-03-30 Armour Pharmaceutical Company 5'-(8'-Hydroxyquinolyl)guanidine compounds
US4000279A (en) 1974-10-29 1976-12-28 Armour Pharmaceutical Company Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same
KR860002082A (ko) * 1984-08-29 1986-03-26 프랑시스 글로리 자기 변환기 헤드 구조물
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
BR9408342A (pt) 1993-12-17 1997-08-19 Procter & Gamble Compostos de 6-(2-imidazolinilamino) quinoxalina úteis como agonistas de adrenoceptores de alfa-2
TR199901468T2 (xx) 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� guanidinil heterosikl bile�ikleri.
EP0946523A1 (de) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Kondensierte polycyclische 2-aminopyrimidinderivate, ihre herstellung und verwendung als proteininhibitoren von tyrosinkinase

Also Published As

Publication number Publication date
NZ336010A (en) 2001-05-25
RU2194700C2 (ru) 2002-12-20
NO992498D0 (no) 1999-05-25
CN1104422C (zh) 2003-04-02
US6391878B2 (en) 2002-05-21
CZ184099A3 (cs) 1999-11-17
CA2272640C (en) 2003-07-08
NO313912B1 (no) 2002-12-23
US20010000345A1 (en) 2001-04-19
CA2272640A1 (en) 1998-06-04
ZA9710578B (en) 1998-06-25
HUP0000312A2 (hu) 2000-09-28
DE69732244T2 (de) 2006-06-29
AR009145A1 (es) 2000-03-08
BR9713536A (pt) 2000-11-07
ES2236833T3 (es) 2005-07-16
EP0944604A1 (de) 1999-09-29
PE16399A1 (es) 1999-03-12
US6225331B1 (en) 2001-05-01
HUP0000312A3 (en) 2001-12-28
NO992498L (no) 1999-07-26
IL130077A0 (en) 2000-02-29
ID23857A (id) 2000-05-25
CO4910148A1 (es) 2000-04-24
CN1242006A (zh) 2000-01-19
EP0944604B1 (de) 2005-01-12
TR199901468T2 (xx) 1999-10-21
DE69732244D1 (de) 2005-02-17
JP2001506600A (ja) 2001-05-22
AU730369B2 (en) 2001-03-08
KR20000069131A (ko) 2000-11-25
AU5438198A (en) 1998-06-22
WO1998023596A1 (en) 1998-06-04
US20020128481A1 (en) 2002-09-12
SK69799A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
ATE286885T1 (de) Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
ATE275142T1 (de) 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
DE69718351D1 (de) Diaminobenzoesäure derivate als farbstoffvorläufer
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
DE69624115D1 (de) Benzimidazol verbindungen
NO2005009I1 (no) Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
DK0935465T3 (da) Nye substituerede imidazolforbindelser
DE69733362D1 (de) Verbindungen mit analgetischer wirkung
ATE298739T1 (de) Calcylitische verbindungen
DE69824199D1 (de) Lactamverbindungen als metalloprotease-inhibitoren
IT1302004B1 (it) Tioeteri eterociclici come additivi per lubrificanti.
IL130094A0 (en) 2-Imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
DE69722022D1 (de) N-substituierte azaheterocyclische verbindungen
ATE232518T1 (de) Guanidinylamino-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
DE69911586D1 (de) Optisch aktive epoxyverbindungen
IL132384A0 (en) 5-(2-Imidazolinylamino) benzimidazole compounds useful as alpha - 2 adrenoceptor agonists
DE59811182D1 (de) Heterocyclische Verbindungen
DE69121413D1 (de) Pyridyl-pyrimidinderivate als fungizide verbindungen
ZA9710574B (en) 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists.
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
IL130067A0 (en) 2-Imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
ATE228143T1 (de) 14.beta.,17-alpha-hydroxymethylandrostan derivate als androgene
DE69500294D1 (de) Benzoheterocyclische Verbindungen als Antioxidantien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties